Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) have been assigned a consensus rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $51.75.

A number of research analysts have recently issued reports on PSTV shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a report on Friday, July 17th. Ascendiant Capital Markets dropped their price objective on Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Monday, June 8th.

Plus Therapeutics Stock Performance

NASDAQ:PSTV opened at $2.94 on Friday. The firm has a market cap of $20.24 million, a P/E ratio of -1.28 and a beta of 1.40. Plus Therapeutics has a fifty-two week low of $2.90 and a fifty-two week high of $23.42. The firm has a 50-day simple moving average of $3.67 and a two-hundred day simple moving average of $5.12.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, August 13th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.43). Plus Therapeutics had a negative return on equity of 198.48% and a negative net margin of 230.24%.The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.11 million. On average, equities research analysts predict that Plus Therapeutics will post -3.76 EPS for the current year.

Hedge Funds Weigh In On Plus Therapeutics

Several institutional investors have recently made changes to their positions in PSTV. Virtu Financial LLC bought a new stake in shares of Plus Therapeutics during the 4th quarter valued at $254,000. State Street Corp raised its holdings in Plus Therapeutics by 37.1% in the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock worth $240,000 after purchasing an additional 127,000 shares during the period. Jane Street Group LLC purchased a new position in Plus Therapeutics during the fourth quarter valued at $525,000. Geode Capital Management LLC lifted its position in Plus Therapeutics by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after purchasing an additional 589,544 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Plus Therapeutics during the fourth quarter valued at about $127,000. Institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical?stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.